Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A real-world study finds sparsentan cuts protein loss fast in kidney disease patients. In 41 patients with IgA nephropathy already on optimized therapy — including SGLT2 inhibitors — sparsentan reduced proteinuria by over 50% in half of patients within just 3 months. Kidney function stayed stable throughout the 12-month follow-up, and the safety profile looked reassuring.
A real-world retrospective study across 14 Spanish centres found that sparsentan delivered meaningful and durable reductions in proteinuria for patients with IgA nephropathy (IgAN) — even in those already on optimized background therapy. The study included 41 patients with biopsy-proven IgAN, nearly all of whom were on SGLT2 inhibitors and maximum-tolerated renin-angiotensin system blockade before starting sparsentan.
The results were encouraging: half of patients hit the primary target of a >50% proteinuria reduction at just 3 months, and that benefit held up through 6 and 12 months of follow-up. Kidney function, measured by estimated glomerular filtration rate, remained stable throughout — a key win given the progressive nature of IgAN.
By the Numbers:
Why it matters: IgA nephropathy is the most common primary glomerular disease worldwide and a leading cause of kidney failure. This study adds real-world evidence that sparsentan can meaningfully reduce proteinuria — a key driver of disease progression — even on top of already-optimized modern therapy, strengthening its case as a valuable treatment option.
